151 related articles for article (PubMed ID: 38037189)
1. A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma.
Germani MM; Boccaccio C; Matrone A; Molinaro E; Alì G; Giordano M; Elisei R; Fontanini G; Cremolini C
Oncologist; 2024 Jan; 29(1):84-88. PubMed ID: 38037189
[TBL] [Abstract][Full Text] [Related]
2. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
[TBL] [Abstract][Full Text] [Related]
3. NTRK Fusion in a Cohort of BRAF p. V600E Wild-Type Papillary Thyroid Carcinomas.
Lee SE; Lee MS; Bang H; Kim MY; Choi YL; Oh YL
Mod Pathol; 2023 Aug; 36(8):100180. PubMed ID: 37003481
[TBL] [Abstract][Full Text] [Related]
4. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).
Chu YH; Dias-Santagata D; Farahani AA; Boyraz B; Faquin WC; Nosé V; Sadow PM
Mod Pathol; 2020 Nov; 33(11):2186-2197. PubMed ID: 32457407
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
7. An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion.
Bargas S; Mc Leer A; Mondet J; Chabre O; Laramas M
Eur J Endocrinol; 2022 Feb; 186(4):K5-K8. PubMed ID: 35118995
[TBL] [Abstract][Full Text] [Related]
8. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
9. How Sensitive is Pan-TRK Immunohistochemistry for Detecting NTRK Fusions in Papillary Thyroid Carcinoma?
Hang JF; Lee YC
Mod Pathol; 2023 Jul; 36(7):100222. PubMed ID: 37336120
[No Abstract] [Full Text] [Related]
10. Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
Haddad R; Elisei R; Hoff AO; Liu Z; Pitoia F; Pruneri G; Sadow PM; Soares F; Turk A; Williams MD; Wirth LJ; Cabanillas ME
JAMA Oncol; 2023 Aug; 9(8):1132-1141. PubMed ID: 37289450
[TBL] [Abstract][Full Text] [Related]
11. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of the methods for detecting NTRK gene fusion variations in papillary thyroid carcinoma].
Jiang YY; Chen H; Xu BL; Wang S
Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):726-732. PubMed ID: 35922162
[No Abstract] [Full Text] [Related]
13. Fine-needle aspiration cytomorphology of papillary thyroid carcinoma with NTRK gene rearrangement from a case series with predominantly indeterminate cytology.
Abi-Raad R; Prasad ML; Adeniran AJ; Cai G
Cancer Cytopathol; 2020 Nov; 128(11):803-811. PubMed ID: 32931153
[TBL] [Abstract][Full Text] [Related]
14.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
15. Molecular and Cytogenetic Features of NTRK Fusions Enriched in BRAF and RET Double-Negative Papillary Thyroid Cancer.
Wu S; Liu Y; Li K; Liang Z; Zeng X
J Mol Diagn; 2023 Aug; 25(8):569-582. PubMed ID: 37236546
[TBL] [Abstract][Full Text] [Related]
16. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.
Kong Y; Bu R; Parvathareddy SK; Siraj AK; Siraj N; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Eur J Endocrinol; 2021 Apr; 184(4):503-511. PubMed ID: 33524004
[TBL] [Abstract][Full Text] [Related]
17. NTRK fusions in thyroid cancer: Pathology and clinical aspects.
Ma Y; Zhang Q; Zhang K; Liang Y; Ren F; Zhang J; Kan C; Han F; Sun X
Crit Rev Oncol Hematol; 2023 Apr; 184():103957. PubMed ID: 36907364
[TBL] [Abstract][Full Text] [Related]
18. NTRK-rearranged papillary thyroid carcinoma demonstrates frequent subtle nuclear features and indeterminate cytologic diagnoses.
Lee YC; Hsu CY; Lai CR; Hang JF
Cancer Cytopathol; 2022 Feb; 130(2):136-143. PubMed ID: 34644010
[TBL] [Abstract][Full Text] [Related]
19. Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.
Liu M; Chen P; Hu HY; Ou-Yang DJ; Khushbu RA; Tan HL; Huang P; Chang S
J Cancer Res Clin Oncol; 2021 Feb; 147(2):323-337. PubMed ID: 33387037
[TBL] [Abstract][Full Text] [Related]
20. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]